(Q42451927)

31 October 2017

title

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma (English)

1 reference

31 October 2017

1 reference

1 reference

Michele Reni

1

1 reference

31 October 2017

Stefano Cereda

2

1 reference

31 October 2017

Gianpaolo Balzano

3

1 reference

31 October 2017

Paolo Passoni

4

1 reference

31 October 2017

Alessia Rognone

5

1 reference

31 October 2017

Clara Fugazza

6

1 reference

31 October 2017

Elena Mazza

7

1 reference

31 October 2017

Alessandro Zerbi

8

1 reference

31 October 2017

Valerio Di Carlo

9

1 reference

31 October 2017

Eugenio Villa

10

1 reference

31 October 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

31 October 2017

1 reference

31 October 2017

volume

115

1 reference

31 October 2017

issue

12

1 reference

31 October 2017

page(s)

2630-2639

1 reference

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

On the relationship between response to treatment and survival time

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24302

7 January 2021

Identifiers

DOI

10.1002/CNCR.24302

1 reference

31 October 2017

1 reference